CSPC PHARMA's Novel KAT 6 Inhibitor Receives FDA Clearance for U.S. Clinical Trials

CSPC PHARMA (01093) announced that SYH2095 tablets, a new Class 1 chemical drug developed in collaboration with Hangzhou Yingchuang Medicine Technology Co., Ltd., have received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States. SYH2095 is a novel, highly selective lysine acetyltransferase 6 (KAT 6) inhibitor, which belongs to a class of epigenetic anti-cancer drugs. The product exerts its anti-tumor effects by inhibiting the acetylation of histone lysines, blocking open chromatin, and thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies indicate that SYH2095 demonstrates highly potent and selective inhibition of KAT 6, significantly suppressing tumor growth while exhibiting favorable pharmacokinetic properties and a good safety profile. Currently, no drugs targeting this mechanism are approved for market use globally, highlighting the significant clinical development potential of this product.